Latest Elixir Pharmaceuticals Inc. Stories
Elixir Pharmaceuticals, Inc., today announced the Company has entered an exclusive license agreement with Boston University to key intellectual property covering discoveries regarding the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.
Elixir Pharmaceuticals, Inc., today announced that results from in-vivo preclinical studies with the Company's ghrelin agonist, EX-1314, were presented at the annual meeting of the Endocrine Society. EX-1314 is expected to enter human clinical testing this year.
- The act of sweetening by admixture of some saccharine substance.